Efficacy evaluation of current and future platelet transfusion products

Journal of Trauma - Injury, Infection and Critical Care

Volumn 60, Issue 6 SUPPL., 2006, Pages

  Vostal, Jaroslav G ^a,b  

^a Center for Biologics Evaluation and Research   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; SAFETY; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS;

EID: 33745134379     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000199921.40502.5d     Document Type: Conference Paper

References (7)

1. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18:153-167.
2. FDA: Draft Guidance for Industry: Platelet Testing and Evaluation of Platelet Substitute Products. Available at: http://wwwfdagov/cber/gdlns/ platelethtm. Accessed 1999.
3. Murphy S. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion. 2004;44:131-133.
4. FDA: Workshop on the Use of Radiolabeled Platelets for Assessment of In Vivo Viability of Platelet Products. Available at: http://www.fda.gov/cber/ minutes/radioplt050304.htm. Accessed 2004.
5. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:204-214.
6. Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion. 2004;44:605-617.
7. FDA: Workshop on safety and efficacy of methods for reducing pathogens in cellular blood products used in transfusion. Available at: http://www.fda.gov/ cber/minutes/pathtrans080702.htm. Accessed 2003.